Motugivatrep introduces first-in-class topical TRPV1 antagonism for DED, targeting corneal nociceptor-driven discomfort ...
Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 ...
Hyloris Pharmaceuticals SA has announced the development of HY-083, a new proprietary intranasal formulation of a TRPV1 agonist to treat idiopathic rhinitis. Hyloris' treatment approach is to activate ...
Researchers at Kanazawa University report in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) high-speed atomic force microscopy experiments that show how ...
Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.
Researchers have made a discovery regarding the TRPV1 (transient receptor potential vanilloid 1) ion channel and its role in pain perception. The study reveals how solvent molecules can modulate pain ...
Chronic pain is known to shorten lifespan, and pain tends to increase with age. But is there a relationship between pain and longevity? Researchers have found that mice lacking the capsaicin pain ...
By comparing osteoarthritis pain pathways known to be active in dogs and humans to those in cats with degenerative joint disease (DJD), researchers found that elevation of a particular molecule, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results